Latest placebo Stories
Recent studies prove turmeric reduces tryiglicerdies, chronic inflammation while proving antioxidant support improving cardiovascular health Rancho Palos Verdes, CA (PRWEB) October 10, 2012 Benefit6 Whole Body Protection by I Do Strive, LLC is the first product to focus on six key areas of health to provide consumers with the most comprehensive whole body protection supplement including reducing chronic inflammation. Research from Penn State finds the spice turmeric does the heart good by...
Multiple sclerosis and extract of cannabis: Results of the MUSEC trial Up to 90 per cent of MS patients endure painful muscle stiffness at some point during the course of their disease, which reduces their mobility and interferes with daily routine activities and sleep quality. But current treatments often fail to resolve symptoms fully, and can be harmful, as a result of which many MS patients have experimented with alternative therapies, including cannabis. Adult MS patients with...
The primary objective of this study is to evaluate the efficacy of a new drug compared with a placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe Chronic Lower Back Pain. DeLand, Florida (PRWEB) October 08, 2012 Today, there isn’t a ‘one pill’ treatment that either treats or cures back pain. At best there is a multidisciplinary approach that uses a combination of medication and lifestyle changes that seem to work to a degree. In many cases patients who...
INDIANAPOLIS, Oct. 8, 2012 /PRNewswire/ -- Lilly's analysis, as previously reported, showed primary endpoints, both cognitive and functional, were not met in the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease In Lilly's pre-specified secondary analysis of pooled data in patients with mild Alzheimer's disease, a statistically significant slowing of cognitive decline was shown; this finding...
OXFORD, England, October 4, 2012 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune(R) cat allergy treatment for cat allergen-induced rhinoconjunctivitis. The multinational study in almost 1,200 subjects incorporates input from leading medical experts from Europe and North America, and follows a constructive End of Phase 2 meeting with the US Food...
Kronos Early Estrogen Prevention Study results to help clinicians assess HT risk-benefits PHOENIX, Oct. 3, 2012 /PRNewswire-USNewswire/ -- Kronos Longevity Research Institute (KLRI) today announced that a major finding of the Kronos Early Estrogen Prevention Study (KEEPS) indicates that hormone therapy (HT) improves symptoms of depression and anxiety in recently menopausal women, without adverse effects on cognition. The findings come as a result of a four-year randomized clinical...
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA. Data on treatment of NDMs are largely anecdotal, consisting of case series and a single-blind, controlled trials of several medications including...
MENLO PARK, Calif., Oct. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today that it is presenting two abstracts from its Phase 3 clinical trial, BREEZE 3, at this week's 23(rd) Annual Meeting of the North American Menopause Society (NAMS) in Orlando, FL. The data showed that Serada(®), Depomed's investigational non-hormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes. "Hot flashes are a disruptive problem affecting as many as...
MIAMI, FL, NEW YORK, NY and ORLANDO, FL, Oct. 3, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Menopausal VMS, which comprise hot...
NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Lonza, a global leader in the life sciences industry, is pleased to announce the launch of Alomune, a safe, daily immune supplement made with natural extracts from the renewable Minnesota Larch Tree that optimize the body's immune response to help people stay healthy. "We are extremely pleased to introduce Alomune to the market," said Marshall Fong, Director of Consumer Marketing for Lonza. "Unlike many other immune products currently...
